| Literature DB >> 27684328 |
Nicola Beresford1, Alice Baynes1, Rakesh Kanda2, Matthew R Mills3, Karla Arias-Salazar3, Terrence J Collins3, Susan Jobling1.
Abstract
Endocrine Disrupting Compounds pose a substantial risk to the aquatic environment. Ethinylestradiol (EE2) and estrone (E1) have recently been included in a watch list of environmental pollutants under the European Water Framework Directive. Municipal wastewater treatment plants are major contributors to the estrogenic potency of surface waters. Much of the estrogenic potency of wastewater treatment plant (WWTP) effluents can be attributed to the discharge of steroid estrogens including estradiol (E2), EE2 and E1 due to incomplete removal of these substances at the treatment plant. An evaluation of the efficacy of wastewater treatment processes requires the quantitative determination of individual substances most often undertaken using chemical analysis methods. Most frequently used methods include Gas Chromatography-Mass Spectrometry (GCMS/MS) or Liquid Chromatography-Mass Spectrometry (LCMS/MS) using multiple reaction monitoring (MRM). Although very useful for regulatory purposes, targeted chemical analysis can only provide data on the compounds (and specific metabolites) monitored. Ecotoxicology methods additionally ensure that any by-products produced or unknown estrogenic compounds present are also assessed via measurement of their biological activity. A number of in vitro bioassays including the Yeast Estrogen Screen (YES) are available to measure the estrogenic activity of wastewater samples. Chemical analysis in conjunction with in vivo and in vitro bioassays provides a useful toolbox for assessment of the efficacy and suitability of wastewater treatment processes with respect to estrogenic endocrine disrupting compounds. This paper utilizes a battery of chemical and ecotoxicology tests to assess conventional, advanced and emerging wastewater treatment processes in laboratory and field studies.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27684328 PMCID: PMC5092016 DOI: 10.3791/54243
Source DB: PubMed Journal: J Vis Exp ISSN: 1940-087X Impact factor: 1.355
|
| PL gel, 50 A, 300 x 7.5 mm, 5 µm |
|
| PL gel, 50 x 7.5 mm, 5 µm |
|
| Dichloromethane |
|
| 1 ml per min |
|
| 25 °C |
|
| 210 nm |
|
| 95 µl |
|
| Standard |
|
| 500 ml per min |
|
| 500 ml per min |
|
| 3 mm |
|
| 3 ml fraction (7 - 10 min) in 10 ml vials |
| LCMS | |||||
| Liquid Chromatography | |||||
| Column: | C18(2), 150 x 4.6 mm, 5 μm. | ||||
| Injection volume: | 20 µl | ||||
| Flow: | 0.5 ml per minute. | ||||
| Mobile phase: | Solvent A: water containing 0.1% ammonia. | ||||
| Solvent B: acetonitrile. | |||||
| Gradient program: | |||||
| Time (min) | 0 | 10 | 18 | 24 | 28 |
| A:B solvent ratio | 90:10:00 | 50:50:00 | 0.479167 | 0.479167 | 90:10:00 |
| Mass Spectrometry | |||||
| Source: | Electrospray (negative ion) | ||||
| Gas and source: | CUR: 20 psi, GS1: 70 psi, GS2: 30 psi | ||||
| TEM: 600 °C, CAD gas 5 and IonSpray voltage -900 | |||||
| MRM transitions: | |||||
| E1: | 269/145 & 269/143 | ||||
| E2: | 271/145 & 271/143 | ||||
| EE2: | 295/145 & 295/143 | ||||
| E1-D4 : | 273/147 | ||||
| E2-D4: | 275/147 | ||||
| EE2-D4: | 299/145 |
|
|
| Prepare a Fe2(SO4)3 solution by adding 40 mg of Fe2(SO4)3 to 50 ml of double-distilled water (ddH2O) |
| Add 1 L ddH2O to a 2 L glass beaker |
| Add the following components to the beaker: |
| 13.61 g KH2PO4 |
| 1.98 g (NH4)2SO4 |
| 4.2 g KOH |
| 0.2 g MgSO4 |
| 1 ml of the Fe2(SO4)3 solution |
| 50 mg L-leucine |
| 50 mg L-histidine |
| 50 mg adenine |
| 20 mg L-arginine-HCl |
| 20 mg L-methionine |
| 30 mg L-tyrosine |
| 30 mg L-isoleucine |
| 30 mg L-lysine-HCl |
| 25 mg L-phenylalanine |
| 100 mg L-glutamic acid |
| 150 mg L-valine |
| 375 mg L-serine |
| Put the beaker on heated stirrer with a magnetic flea and stir until it is all dissolved |
| Check that the pH is 7.1 and adjust if necessary |
| Using a 50 ml sterile syringe dispense 45 ml aliquots into glass bottles with metal screw top lids |
| Sterilize the Minimal Medium at 121 °C for 10 min in an autoclave |
| Store at room temperature |
|
|
| Prepare a 20% w/v solution in ddH2O |
| Dispense 20 ml aliquots in to glass vials with metal screw top lids |
| Sterilize the Glucose solution at 121 °C for 10 min in an autoclave |
| Store at room temperature |
|
|
| Make a stock solution of 4 mg/ml in ddH2O |
| Dispense 20 ml aliquots in to glass vials with metal screw top lids |
| Sterilize the L-Aspartic Acid solution at 121 °C for 10 min in an autoclave |
| Store at room temperature |
|
|
| Prepare a biotin solution by adding 2 mg of biotin to 100 ml of ddH2O |
| Weigh out 8 mg thiamine, 8 mg pyridoxine, 8 mg pantothenic acid, 40 mg inositol. Add all the dry components and 20 ml of the biotin solution to 180 ml ddH2O |
| Make 10 ml sterile aliquots by filtering through a 0.2-µm pore size disposable filter into sterile glass bottles, in a laminar air flow cabinet |
| Store at 4 °C |
|
|
| Prepare 100 ml of 24 mg/ml L-threonine in ddH2O |
| Dispense 10 ml aliquots in to glass vials with metal screw top lids |
| Sterilize the L-threonine solution at 121 °C for 10 min in an autoclave |
| Store at room temperature |
|
|
| Prepare 25 ml of a 20 mM Copper(II) Sulfate solution in ddH2O |
| Make 5 ml sterile aliquots by filtering through a 0.2-µm pore size filter into sterile glass bottles, in a laminar flow cabinet |
| Store at room temperature |
|
|
| Prepare 25 ml of a 10 mg/ml solution of CPRG in ddH2O |
| Make 5 ml sterile aliquots by filtering through a 0.2-µm pore size filter into sterile glass bottles, in a laminar flow cabinet |
| Store at 4 °C |
|
|
|
|
|
|
| 70% IMS | Dehydration | 3 |
|
| 90% IMS | Dehydration | 2.5 |
|
| 95% IMS | Dehydration | 1.5 |
|
| 100% IMS | Dehydration | 1.5 |
|
| 100% IMS | Dehydration | 1.5 |
|
| 100% IMS | Dehydration | 1.5 |
|
| 100% IMS | Dehydration | 1.5 |
|
| Histology clearing agent | Clearing | 1.5 |
|
| Histology clearing agent | Clearing | 1.5 |
|
| Histology clearing agent | Clearing | 1.5 |
|
| WAX | Wax infiltration | 1.25 |
|
| WAX | Wax infiltration | 1.25 |
|
|
|
|
|
|
|
|
| Histology Clearing agent | Dissolves wax | 15 |
|
| 100% IMS | Hydration | 2 |
|
| 90% IMS | Hydration | 2 |
|
| 70% IMS | Hydration | 2 |
|
| TAP WATER (RUNNING) | Rinse | 2 |
|
| HAEMOTOXYLIN | Stains cell nuclei blue | 10 |
|
| TAP WATER (RUNNING) | Remove excess | 10 |
|
| Acidified IMS | Dechlorination | 20 sec |
|
| TAP WATER (RUNNING) | Rinse | 20 sec |
|
| LiCO3 | Salt | 20 sec |
|
| TAP WATER (RUNNING) | Rinse | 20 sec |
|
| 1% EOSIN (AQUEOUS) | Stains cytoplasm pink | 20 sec |
|
| TAP WATER (RUNNING) | Remove excess | 5 |
|
| 70% IMS | Dehydration | 2 |
|
| 90% IMS | Dehydration | 2 |
|
| 100% IMS | Dehydration | 5 |
|
| Histology Clearing agent | Remove IMS, binding agent | 5 |
|
|
|
|
| Normal male testis |
|
| Multifocal ovotestis with 1–5 oocytes (usually singly) scattered among the testicular tissue |
|
| Multifocal ovotestis, 6–20 oocytes often in small clusters scattered among the testicular tissue |
|
| Multifocal ovotestis, 21–50 oocytes in clusters |
|
| >50 and <100 oocytes. Section is usually multifocal and has the appearance of a mosaic of testicular and ovarian tissue. |
|
| >100 oocytes, usually multifocal but could also be focal with clearly identifiable zones of ovarian and testicular tissue separated from the testicular tissue. |
|
| >50 per cent of the gonadal tissue on the section is ovarian and is clearly separated from the testicular tissue by epithelial cells and phagocytic tissues. |
|
| 100 per cent of gonadal tissue on the section is ovarian. |